|
Daratumumab and Hyaluronidase-fihj Clinical Trials
4 actively recruiting trials across 3 locations
No change since May 2026
Also known as: DARA Co-formulated with rHuPH20, DARA/rHuPH20, DARZALEX FASPRO, Daratumumab, Daratumumab + rHuPH20 +8 more
Pipeline
Phase 2: 1Phase 3: 3
Top Sponsors
- SWOG Cancer Research Network2
- Suzanne Lentzsch, MD1
- ECOG-ACRIN Cancer Research Group1
Indications
- Cancer4
- Plasma Cell Myeloma2
- Amyloid Light-chain Amyloidosis1
- AL Amyloidosis1
- RISS Stage II Plasma Cell Myeloma1
Anchorage, Alaska2 trials
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Anchorage Associates in Radiation Medicine
Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Anchorage Associates in Radiation Medicine
Phase 3
Goodyear, Arizona1 trial
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
CTCA at Western Regional Medical Center
Phase 3
New York, New York1 trial
Teclistamab-Daratumumab in AL Amyloidosis
Columbia University Irving Medical Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.